Alkermes PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ALKS
Alkermes PLCAlkermes plc reported a decrease in net income for 2025 despite strong proprietary product sales, driven by expiring royalties and increased R&D investments, while completing a major acquisition and advancing its neuroscience pipeline.
NASDAQ
ALKS
Alkermes PLC10-K: Alkermes Reports Strong Financial Results for 2024, Navigates Patent Landscape and Strategic Shifts
Alkermes plc reports a net income of $372.1 million for 2024, driven by proprietary product sales and strategic collaborations, while managing patent challenges and completing the sale of its Athlone facility.
NASDAQ
ALKS
Alkermes PLCAlkermes details its ordinary share structure, dividend restrictions, and potential anti-takeover provisions in its latest SEC filing.